clinical trial · NCT05707351
A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A
Takeda·phase3·completed·n = 37
Hemophilia AAdynovate
brief summary
The main aim of the study is to determine how well Adynovate works to decrease bleeding in previously treated Chinese men and boys with severe hemophilia A when given prophylactically. Participants will be treated with Adynovate twice a week for 26 weeks or until participants have received 50 days of treatment with Adynovate (whichever takes longer). Participants will need to visit their study clinic several times during their participation.
started
Mar 27, 2023
primary completion
Sep 5, 2024
completion
Sep 5, 2024
last updated
May 1, 2025
official title
A Phase 3, Prospective, Multicenter, Open-label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (ADYNOVATE) Administered for Prophylaxis and Treatment of Bleeding in Chinese Previously Treated Patients With Severe Hemophilia A (FVIII <1%)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol